WayPoint Biomedical Accepted as Full Member Into the HIRA Organization
12 Juillet 2006 - 2:00PM
PR Newswire (US)
HUNTINGTON BEACH, Calif., July 12 /PRNewswire-FirstCall/ --
WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH) has been
accepted as a full member into the Health Industry Representatives
Association (HIRA). The Health Industry Representatives Association
focuses on promoting the manufacturers' rep function within the
healthcare industry. Its members are independent sales agencies
located across the nation who offer manufacturers a professional,
highly qualified sales force. Additionally, allied members are
manufacturers who support the continuing use of independent sales
agencies to market their products. HIRA has been in existence since
1980 and enjoys a well respected position in the Health Care
Industry with Manufacturers, Distributors and Rep Groups across the
USA. HIRA also conducts focus groups, helps promote new member
exposure and coordinates a national trade show each year to allow
Manufacturers and Distributor/Rep groups to view new and exciting
products and services. Global Director of Sales & Marketing,
Phill Richer, states, "WayPoint's acceptance by the HIRA
organization will increase the exposure of the company to hundreds
of new manufacturers and rep groups across the USA. We plan to work
very closely with the members and organization to promote and
secure new sources of revenue for our Health Essist(TM) group of
products and our Clinical Drugs of abuse tests." For more
information on HIRA, please visit http://www.hira.org/ . About
WayPoint Biomedical: WayPoint Biomedical, Inc., a wholly owned
subsidiary of WayPoint Biomedical Holdings, Inc. (Pink sheets:
WYPH), is an innovative biomedical technology firm, specializing in
diagnostic tests and devices for screening and monitoring human
health, fitness and environment. The Company develops and markets
cutting-edge disposable rapid tests that offer both a preliminary
diagnostic screen to specific conditions, along with a future path
for consumers, medical providers, and first responders to follow
regarding their health status or environmental condition.
WayPoint's unique and affordable home-based and on-site tests are
focused on detecting the cause of a disease or pathogen, as opposed
to determining the symptom; becoming a part of the solution to help
reverse the escalating cost of Healthcare. The Company's primary
target sectors are the Over the Counter (OTC) Self-Testing Market,
the Diagnostic Point of Care (POC) Testing Market, and the Homeland
Security & Defense Market; three of the fastest growing areas
in all of diagnostic medicine and science. For more information on
WayPoint Biomedical visit http://www.waypointbiomedical.com/ ,
http://www.drinkdetectiveusa.com/ . Included in this release are
certain "forward-looking' statements, involving risks and
uncertainties, which are covered by the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995, including
statements regarding WayPoint's performance. Such statements are
based on management's current expectations and are subject to
certain factors, risks and uncertainties that may cause actual
results, events and performance to differ materially from those
referred to or implied by such statements. In addition, actual
future results may differ materially from those anticipated,
depending on a variety of factors, including continued maintenance
of favorable license arrangements, success of market research
identifying new product opportunities, successful introduction of
new products, continued product innovation, the success of
enhancements to WayPoint's brand image, sales and earnings growth,
ability to attract and retain key personnel, and general economic
conditions affecting consumer spending, including uncertainties
relating to global political conditions, such as terrorism. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. WayPoint
Biomedical does not intend to update any of the forward-looking
statements after the date of this release to conform these
statements to actual results or to changes in its expectations,
except as may be required by law. Dennis Shepherd, 714-848-3200
E-mail: DATASOURCE: WayPoint Biomedical, Inc. CONTACT: Dennis
Shepherd of WayPoint Biomedical, Inc., +1-714-848-3200, Web site:
http://www.drinkdetectiveusa.com/ Web site: http://www.hira.org/
Web site: http://www.waypointbiomedical.com/
Copyright